SKIN X
LIVE

Serial Number

87838002

Owner

CELLINK Bioprinting AB

Attorney

Margarita Wallach, Esq.

Filing Date

Mar 16, 2018

Add to watchlist:

No watchlists yet
View on USPTO

SKIN X Trademark

Serial Number: 87838002 • Registration: 5987245

SKIN X is a trademark filed by CELLINK Bioprinting AB on March 16, 2018. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

CELLINK Bioprinting AB (23 trademarks)

LÃ¥ngfilsgatan 5

Entity Type: 98

CELLINK AB (30 trademarks)

ARVID WALLGRENS BACKE 20
GOTHENBURG 41346 , SE

Entity Type: 03

Trademark Details

Filing Date

March 16, 2018

Registration Date

February 18, 2020

Published for Opposition

October 1, 2019

Goods & Services

Pharmaceutical preparations for use in the field of 3D bio-printing of tissues and organs; Pharmaceutical preparations based on cellulous nano-fibrils for use in the 3D bio-printing of tissues and organs; Tissue-regenerative pharmaceutical preparations; Cells for medical use; Human allograft tissue; Living cells for medical use; Implants of living tissues for guided tissue regeneration; Implants comprising living tissue; Implantable materials of living tissue for use in guided tissue regeneration; Skin grafts; Surgical implants comprised of living tissues; Surgical implants of living tissues grown from stem cells; Transdermal patches for use to create skin for prosthetic limbs and for skin grafts; Living tissues for transplant; Engineered biological tissues and organs, namely, human and animal cardiovascular, pulmonary, digestive, hepatobiliary, urological, renal, endocrine, connective, epithelial, muscular, and nervous tissue and organs, for medical purposes; Biological molecules to assist in the development of tissue; Haemostatic gel matrix preparations for treating wounds; Natural biomaterials for augmentation of bone, blood and tissue for medical purposes; Pharmaceutical products for tissue regeneration, for tissue repair, for tissue treatment, whether relating to human or animal tissue; Pharmaceutical preparations for the treatment of bone diseases, for cartilaginous diseases, for vascular diseases, for neuronal degeneration, for degeneration of tendons and ligaments, for retinal degeneration, for renal degeneration, degeneration of soft tissue, for diseases with abnormal cell proliferation; Natural biomaterials for bone filling; Natural biomaterials for filling cartilage; Biological tissue cultures for medical use; Biological tissue cultures for medical purposes; Biological tissue grafts; Biological bone and skin tissues impregnated with lines of oxygen for tissue engineering applications to increase cell survival in tissue intended for subsequent implantation; Gene therapy products, namely, genetically engineered tissues for transplant purposes; Implantable scaffolds comprising living tissue for maintaining tissue contour; Natural biomaterials for augmentation of bone and tissue for medical purposes

Biologically compatible polymers, namely, hydrogels used to manufacture polymeric networks used in the manufacture of engineered living tissue for medical, scientific and non-scientific purposes; Media for cell culture for use in the biotechnological industry; Media for cell culture for use in non-medical research laboratories; Biological preparation for use in cell cultures other than for medical or veterinary use; Engineered biological tissues and tissue arrays, namely, human and animal organ, connective, epithelial, muscular, and nervous tissues and tissue arrays, for use in scientific and medical research; Biologically compatible materials, namely, hydrogels used to create polymeric networks used in the manufacture of living tissue; Proteins in raw material form for scientific and medical research

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Feb 18, 2025 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 15, 2023 ASGN
REGISTERED-PRINCIPAL REGISTER
Feb 18, 2020 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Jan 14, 2020 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 14, 2020 AITU
NOTICE OF ALLOWANCE CANCELLED
Nov 26, 2019 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Nov 26, 2019 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 26, 2019 NOAM
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 10, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 10, 2019 REAP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 1, 2019 NPUB
PUBLISHED FOR OPPOSITION
Oct 1, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 11, 2019 NONP
ASSIGNED TO LIE
Aug 28, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 27, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 27, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 27, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 27, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 27, 2019 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 9, 2019 GNFN
FINAL REFUSAL E-MAILED
Jul 9, 2019 GNFR
FINAL REFUSAL WRITTEN
Jul 9, 2019 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
May 9, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 8, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 8, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 3, 2018 GNRN
NON-FINAL ACTION E-MAILED
Dec 3, 2018 GNRT
NON-FINAL ACTION WRITTEN
Dec 3, 2018 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 31, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 31, 2018 CRFA
ASSIGNED TO LIE
Oct 24, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 15, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 14, 2018 GNRN
NON-FINAL ACTION E-MAILED
Apr 14, 2018 GNRT
NON-FINAL ACTION WRITTEN
Apr 14, 2018 CNRT
ASSIGNED TO EXAMINER
Apr 6, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 23, 2018 NWOS
NEW APPLICATION ENTERED
Mar 20, 2018 NWAP